In-vitro activity of azithromycin on Chlamydia trachomatis infected, polarized human endometrial epithelial cells

J Antimicrob Chemother. 1993 Jan;31(1):139-50. doi: 10.1093/jac/31.1.139.

Abstract

The in-vitro activity of azithromycin on Chlamydia trachomatis infected human endometrial epithelial cells, both primary and transformed cells growing in a polarized and non-polarized orientation, was analyzed. Addition of azithromycin two hours after adsorption inoculation with continued exposure until 72 h gave an MIC90 and MBC90 of 0.063 and 0.5 mg/L, respectively. In addition, the MBC results were more pronounced in infected cells growing in a polarized orientation. Numerous small fluorescent 'spots' (presumed small abnormal inclusions) were visible in the infected cells exposed to MIC concentrations of azithromycin. Immuno-transmission electron microscopy examination revealed intracellular inclusions filled with chlamydial envelope ghosts. Since standard diagnostic antigen detection methods use anti-envelope antibodies, the aberrant envelope-filled inclusions might be interpreted as viable inclusions by fluorescent microscopy and result in high false positive readings. To simulate treatment of an infected patient, azithromycin was added at 18 h to infected cells containing many reticulate bodies and exposure continued for 54 h after which killing of chlamydiae was seen. The use of polarized human cells may offer a more relevant in-vitro model system for examining the efficacy of antimicrobial action.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Azithromycin
  • Cells, Cultured
  • Chlamydia Infections / microbiology*
  • Chlamydia trachomatis / drug effects*
  • Chlamydia trachomatis / ultrastructure
  • Endometrium / drug effects*
  • Endometrium / microbiology
  • Endometrium / ultrastructure
  • Epithelium / drug effects
  • Epithelium / microbiology
  • Epithelium / ultrastructure
  • Erythromycin / analogs & derivatives*
  • Erythromycin / pharmacology
  • Female
  • Humans
  • Microbial Sensitivity Tests
  • Microscopy, Electron
  • Time Factors
  • Uterine Diseases / microbiology

Substances

  • Erythromycin
  • Azithromycin